Literature DB >> 14673813

Willingness to pay for a QALY.

Dorte Gyrd-Hansen1.   

Abstract

A willingness to pay (WTP) per quality-adjusted-life year (QALY) of DKK 88,000 was estimated on the basis of elicited preferences for health states. The WTP per QALY estimate presented here differs considerably from that implied in contingent valuation studies, suggesting that WTP for reducing risk of death is based on other preference structures than is ex post WTP for improvements in quality of life. Results further suggest that different preference structures may exist when respondents are faced with WTP questions in which case elimination of minor health problems are associated with negligible utility. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 14673813     DOI: 10.1002/hec.799

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  28 in total

1.  Exploring a new method for deriving the monetary value of a QALY.

Authors:  Carl Tilling; Marieke Krol; Arthur E Attema; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2015-08-20

2.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 3.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

Review 5.  Health economic benefits from optimized meal services to older adults-a literature-based synthesis.

Authors:  Jørgen Dejgård Jensen
Journal:  Eur J Clin Nutr       Date:  2020-08-14       Impact factor: 4.016

6.  The societal monetary value of a QALY associated with EQ-5D-3L health gains.

Authors:  Laura Vallejo-Torres; Borja García-Lorenzo; Oliver Rivero-Arias; José Luis Pinto-Prades
Journal:  Eur J Health Econ       Date:  2019-11-28

Review 7.  Cost-effectiveness acceptability curves and a reluctance to lose.

Authors:  Johan L Severens; Daniëlle E M Brunenberg; Elisabeth A L Fenwick; Bernie O'Brien; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.

Authors:  Joshua A Roth; Ruth Etzioni; Teresa M Waters; Mary Pettinger; Jacques E Rossouw; Garnet L Anderson; Rowan T Chlebowski; Joann E Manson; Mark Hlatky; Karen C Johnson; Scott D Ramsey
Journal:  Ann Intern Med       Date:  2014-05-06       Impact factor: 25.391

9.  Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Authors:  Tracy A Lieu; G Thomas Ray; Ismael R Ortega-Sanchez; Ken Kleinman; Donna Rusinak; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Willingness to pay for cancer prevention.

Authors:  Timothy L Hunt; Bryan R Luce; Matthew J Page; Robin Pokrzywinski
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.